Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03099564
Recruitment Status : Active, not recruiting
First Posted : April 4, 2017
Last Update Posted : March 23, 2022
Merck Sharp & Dohme LLC
Hoosier Cancer Research Network
Information provided by (Responsible Party):
Ashwin Somasundaram, Hoosier Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : May 19, 2021
Estimated Study Completion Date : July 2022